ClinicalTrials.gg
Active, not recruitingNCT02246621MONARCH 3Updated Feb 3, 2026Results posted

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

A Phase 3 interventional study of Abemaciclib and Anastrozole in Breast Cancer, sponsored by Eli Lilly and Company. Active, not recruiting at 155 sites in 22 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
493
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.

Enrollment
6th of 55
493 · median 120
Started
2014
with 3 others
Phase 3
11 of 55
2 open now
Primary completion
2017-01
later than 0 of 33 live
Registered
4th of 55
by date
Lead sponsor
17 of 55
Eli Lilly and Company

Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 6th largest by enrollment, is one of 4 that started in 2014, is one of 11 in phase 3, reaches primary completion later than 0 of the 33 other live ones, and was the 4th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing abemaciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate how effective nonsteroidal aromatase inhibitors (NSAI) plus abemaciclib are in postmenopausal women with breast cancer. Participants will be randomized to abemaciclib or placebo in a 2:1 ratio.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • MONARCH 3
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (-) breast cancer
  • Have locoregionally recurrent disease not amenable to resection or radiation therapy with curative intent or disease
  • Have status
  • Have either or nonmeasurable bone-only disease
  • Have a performance status ≤1 on the (ECOG) scale
  • Have adequate organ function
  • Have discontinued previous localized radiotherapy for palliative purposes or for lytic lesions at risk of fracture prior to randomization and recovered from the acute effects of therapy
  • Are able to swallow capsules

Exclusion criteria

Exclusion Criteria:

  • Have visceral crisis, lymphangitic spread, or
  • Have inflammatory breast cancer
  • Have clinical evidence or a history of central nervous system (CNS)
  • Are currently receiving or have previously received endocrine therapy for locoregionally recurrent or metastatic breast cancer
  • Have received prior (neo) endocrine therapy with a disease-free interval ≤12 months from completion of treatment
  • Are currently receiving or have previously received chemotherapy for locoregionally recurrent or metastatic breast cancer
  • Have received prior treatment with everolimus
  • Have received prior treatment with any cyclin-dependent kinase (CDK) 4/6 inhibitor (or participated in any CDK4/6 inhibitor clinical trial for which treatment assignment is still blinded)
  • Have initiated bisphosphonates or approved receptor activator of nuclear factor kappa-B ligand (RANK-L) targeted agents \<7 days prior to randomization
  • Are currently receiving an drug in a clinical trial or participating in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of randomization for a nonmyelosuppressive or myelosuppressive agent, respectively
  • Have had major surgery within 14 days prior to randomization
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
493 participants (actual)

Study arms

  • Experimental
    Abemaciclib + NSAI

    150 milligrams (mg) Abemaciclib orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).

    Drug: Abemaciclib · Drug: Anastrozole · Drug: Letrozole

  • Placebo comparator
    Placebo + NSAI

    Placebo orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).

    Drug: Anastrozole · Drug: Letrozole · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS defined as the time from the first day of therapy to the first evidence of disease progression as defined by RECIST v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.

    Time frame: Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months)

Secondary outcomes

  1. Overall Survival (OS)

    OS defined as the time from first dose date to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.

    Time frame: Randomization to Progressive Disease or Death Due to Any Cause (Estimated Up to 82 Months)

  2. Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])

    ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.

    Time frame: Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months)

  3. Duration of Response (DoR)

    DOR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date.

    Time frame: CR or PR to Disease Progression or Death Due to Any Cause (Up to 32 Months)

  4. Percentage of Participants With CR, PR or Stable Disease (SD) (Disease Control Rate [DCR])

    DCR was the percentage of participants with a best overall response of CR, PR, or SD as per response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions.

    Time frame: Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months)

  5. Percentage of Participants With Tumor Response of SD for at Least 6 Months, PR, or CR (Clinical Benefit Rate [CBR])

    CBR defined as percentage of participants with best overall response of CR, PR, or SD with a duration of at least 6 months. CR, PR, or SD were defined using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Percentage of participants = (participants with CR+PR+SD with a duration of at least 6 months / number of participants enrolled) \* 100.

    Time frame: Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months)

  6. Change From Baseline to End of Study in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Functional Scale Scores

    EORTC QLQ-C30 v3.0 is a self-administered questionnaire with multidimensional scales that measures 5 functional domains(physical,role,cognitive,emotional, and social),global health status, and symptom scales of fatigue, pain, nausea and vomiting,dyspnea,loss of appetite,insomnia,constipation and diarrhea, and financial difficulties.Functional scale options are defined on a 7-point scale ranging from 1, "Very poor" to 7, "Excellent". A linear transformation is applied to standardize the raw scores to range between 0 and 100 with higher score indicating better functioning. For functional domains and global health status, higher scores represent a better level of functioning. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, Visit, Treatment\*Visit and Baseline.

    Time frame: Baseline, End of Study (Up to 32 Months)

  7. Change From Baseline to End of Study in Symptom Burden on the EORTC QLQ-C30 Symptom Scale Scores

    EORTC QLQ-C30 v3.0 is a self-administered questionnaire with multidimensional scales that measures 5 functional domains (physical, role, cognitive, emotional, and social), global health status, and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation and diarrhea, and financial difficulties. Symptom scale ranges from: 1, "Not at all"; 2, "A little"; 3, "Quite a bit"; to 4, "Very much." A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For symptoms scales, higher scores indicated greater symptom burden. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, Visit, Treatment\*Visit and Baseline. Small changes are generally defined as at least a 3, 4 or 5 point change from baseline.

    Time frame: Baseline, End of Study (Up to 32 Months)

  8. Change From Baseline to End of Study in Symptom Burden on the EORTC QLQ-Breast23 Questionnaire

    The EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and four symptom scales (systemic side effects, breast symptoms, arm symptoms, upset by hair loss). QLQ-BR23 questionnaire employs 4-point scales with responses from: 1, "Not at all"; 2, "A little"; 3, "Quite a bit"; to 4, "Very much". All scores are converted to a 0 to 100 scale. A higher score representing a higher ("better") level of functioning (BR23: body image, sexual functioning, future perspective), or a higher ("worse") level of symptoms. Least Square (LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, Visit, Treatment\*Visit and Baseline.

    Time frame: Baseline, End of Study (Up to 32 Months)

  9. Change From Baseline to End of Study in Health Status on the EuroQuol 5-Dimension 5 Level (EuroQol-5D 5L) Index Value

    The EuroQol-5D (version 5L) is a brief self-administered, validated instrument consisting of 2 parts.The first part consists of 5 descriptors of current health state (mobility, self care, usual activities, pain/discomfort, and anxiety/ depression); a participant is asked to rate each state on a five level scale (no problem, slight problem, moderate problem, severe problem and extreme problem) with higher levels indicating greater severity/ impairment. Published weights are available that allow for the creation of a single summary score called the EQ-5D index that ranges from 0 to 1, with low scores representing a higher level of dysfunction and 1 as perfect health. Minimally important differences in the EQ-5D index score are 0.06 or greater in cancer patients. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, Visit, Treatment\*Visit and Baseline.

    Time frame: Baseline, End of Study (Up to 32 Months)

  10. Change From Baseline to End of Study in Health Status on the EuroQol-5D 5L Visual Analog Scale (VAS) Scores Scale

    The EuroQol-5D (version 5L) is a brief self-administered, validated instrument consisting of 2 parts. The second part consists of the EQ-5D general health status as measured by a visual analog scale (EQ-5D VAS). EQ-5D VAS measures the participant's self-rated health status on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state). Minimally important differences in the EQ-5D VAS score are 7 or greater in cancer patients. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, Visit, Treatment\*Visit and Baseline.

    Time frame: Baseline, End of Study (Up to 32 Months)

  11. Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity [AUC(0-∞)] of Abemaciclib and Its Metabolites M2 and M20

    Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity \[AUC(0-∞)\] of Abemaciclib and Its Metabolites M2 and M20

    Time frame: Cycle 1 Day 1; 2 to 4 hours (h) post dose, Cycle 2 Day 1; 3 h post dose; 7 h post dose, Cycle 3 Day 1; pre dose, 3 h post dose

  12. PK: Hepatic Clearance of Abemaciclib, and Apparent Hepatic Clearance of Its Metabolites M2 and M20

    PK: Hepatic Clearance of Abemaciclib, and apparent hepatic clearance of its Metabolites M2 and M20

    Time frame: Cycle 1 Day 1; 2 to 4 hours (h) post dose, Cycle 2 Day 1; 3 h post dose; 7 h post dose, Cycle 3 Day 1; pre dose, 3 h post dose

07

Results

Posted Mar 23, 2018

Participant flow

Participant flow — Overall Study
MilestoneAbemaciclib + NSAI (Nonsteroidal Aromatase Inhibitors)Placebo + NSAI
Started328165
Received at least one dose of study drug327161
Completed6330
Not completed265135
Withdrew: Withdrawal by subject2816
Withdrew: Lost to follow-up10
Withdrew: On study treatment/ follow up236119

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS defined as the time from the first day of therapy to the first evidence of disease progression as defined by RECIST v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.

Time frame:
Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsAbemaciclib + NSAIPlacebo + NSAI
Progression Free Survival (PFS)28.18 (23.51 to NA)14.76 (11.24 to 19.20)
Statistical analysis
  • Abemaciclib + NSAI vs Placebo + NSAI · Log Rank · p = 0.000002 · Hazard ratio (hr): 0.54 · 95% CI 0.418 to 0.698
SecondaryOverall Survival (OS)

OS defined as the time from first dose date to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.

Time frame:
Randomization to Progressive Disease or Death Due to Any Cause (Estimated Up to 82 Months)

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])

ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.

Time frame:
Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])
Percentage of ParticipantsAbemaciclib + NSAIPlacebo + NSAI
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])49.7 (44.3 to 55.1)37 (29.6 to 44.3)
Statistical analysis
  • Abemaciclib + NSAI vs Placebo + NSAI · Cochran-Mantel-Haenszel · p = 0.005
SecondaryDuration of Response (DoR)

DOR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date.

Time frame:
CR or PR to Disease Progression or Death Due to Any Cause (Up to 32 Months)
Reported as:
Median · Months
Duration of Response (DoR)
MonthsAbemaciclib + NSAIPlacebo + NSAI
Duration of Response (DoR)27.39 (25.74 to NA)17.46 (11.21 to 22.19)
SecondaryPercentage of Participants With CR, PR or Stable Disease (SD) (Disease Control Rate [DCR])

DCR was the percentage of participants with a best overall response of CR, PR, or SD as per response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions.

Time frame:
Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With CR, PR or Stable Disease (SD) (Disease Control Rate [DCR])
Percentage of ParticipantsAbemaciclib + NSAIPlacebo + NSAI
Percentage of Participants With CR, PR or Stable Disease (SD) (Disease Control Rate [DCR])88.7 (85.3 to 92.1)86.7 (81.5 to 91.9)
Statistical analysis
  • Abemaciclib + NSAI vs Placebo + NSAI · Cochran-Mantel-Haenszel · p = 0.501
SecondaryPercentage of Participants With Tumor Response of SD for at Least 6 Months, PR, or CR (Clinical Benefit Rate [CBR])

CBR defined as percentage of participants with best overall response of CR, PR, or SD with a duration of at least 6 months. CR, PR, or SD were defined using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Percentage of participants = (participants with CR+PR+SD with a duration of at least 6 months / number of participants enrolled) \* 100.

Time frame:
Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Tumor Response of SD for at Least 6 Months, PR, or CR (Clinical Benefit Rate [CBR])
Percentage of ParticipantsAbemaciclib + NSAIPlacebo + NSAI
Percentage of Participants With Tumor Response of SD for at Least 6 Months, PR, or CR (Clinical Benefit Rate [CBR])78.0 (73.6 to 82.5)71.5 (64.6 to 78.4)
Statistical analysis
  • Abemaciclib + NSAI vs Placebo + NSAI · Cochran-Mantel-Haenszel · p = 0.101
SecondaryChange From Baseline to End of Study in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Functional Scale Scores

EORTC QLQ-C30 v3.0 is a self-administered questionnaire with multidimensional scales that measures 5 functional domains(physical,role,cognitive,emotional, and social),global health status, and symptom scales of fatigue, pain, nausea and vomiting,dyspnea,loss of appetite,insomnia,constipation and diarrhea, and financial difficulties.Functional scale options are defined on a 7-point scale ranging from 1, "Very poor" to 7, "Excellent". A linear transformation is applied to standardize the raw scores to range between 0 and 100 with higher score indicating better functioning. For functional domains and global health status, higher scores represent a better level of functioning. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, Visit, Treatment\*Visit and Baseline.

Time frame:
Baseline, End of Study (Up to 32 Months)
Reported as:
Least squares mean · score on a scale
Change From Baseline to End of Study in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Functional Scale Scores
score on a scaleAbemaciclib + NSAIPlacebo + NSAI
Physical-1.0 ± 0.91.7 ± 1.2
Role-1.4 ± 1.12.9 ± 1.6
Emotional4.7 ± 0.94.0 ± 1.3
Cognitive-4.0 ± 0.9-4.0 ± 1.3
Social-0.1 ± 1.03.3 ± 1.4
SecondaryChange From Baseline to End of Study in Symptom Burden on the EORTC QLQ-C30 Symptom Scale Scores

EORTC QLQ-C30 v3.0 is a self-administered questionnaire with multidimensional scales that measures 5 functional domains (physical, role, cognitive, emotional, and social), global health status, and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation and diarrhea, and financial difficulties. Symptom scale ranges from: 1, "Not at all"; 2, "A little"; 3, "Quite a bit"; to 4, "Very much." A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For symptoms scales, higher scores indicated greater symptom burden. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, Visit, Treatment\*Visit and Baseline. Small changes are generally defined as at least a 3, 4 or 5 point change from baseline.

Time frame:
Baseline, End of Study (Up to 32 Months)
Reported as:
Least squares mean · score on a scale
Change From Baseline to End of Study in Symptom Burden on the EORTC QLQ-C30 Symptom Scale Scores
score on a scaleAbemaciclib + NSAIPlacebo + NSAI
Fatigue2.4 ± 1.0-2.6 ± 1.4
Nausea and Vomiting2.4 ± 0.6-0.4 ± 0.9
Pain-4.8 ± 1.0-5.7 ± 1.5
Dyspnea0.9 ± 1.0-1.6 ± 1.4
Insomnia-1.7 ± 1.2-4.1 ± 1.7
Appetite loss0.2 ± 1.1-3.9 ± 1.6
Constipation-0.8 ± 0.91.6 ± 1.3
Diarrhea18.2 ± 1.0-0.5 ± 1.5
Financial difficulties-0.7 ± 1.1-1.2 ± 1.6
SecondaryChange From Baseline to End of Study in Symptom Burden on the EORTC QLQ-Breast23 Questionnaire

The EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and four symptom scales (systemic side effects, breast symptoms, arm symptoms, upset by hair loss). QLQ-BR23 questionnaire employs 4-point scales with responses from: 1, "Not at all"; 2, "A little"; 3, "Quite a bit"; to 4, "Very much". All scores are converted to a 0 to 100 scale. A higher score representing a higher ("better") level of functioning (BR23: body image, sexual functioning, future perspective), or a higher ("worse") level of symptoms. Least Square (LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, Visit, Treatment\*Visit and Baseline.

Time frame:
Baseline, End of Study (Up to 32 Months)
Reported as:
Least squares mean · score on a scale
Change From Baseline to End of Study in Symptom Burden on the EORTC QLQ-Breast23 Questionnaire
score on a scaleAbemaciclib + NSAIPlacebo + NSAI
Body image-4.5 ± 1.10.6 ± 1.6
Sexual functioning-0.2 ± 0.7-0.1 ± 1.0
Future perspective12.7 ± 1.311.9 ± 1.9
Systemic therapy side effects8.15 ± 0.683.68 ± 0.98
Breast symptoms-6.12 ± 0.64-6.23 ± 0.93
Arm symptoms-1.14 ± 0.87-2.23 ± 1.27
SecondaryChange From Baseline to End of Study in Health Status on the EuroQuol 5-Dimension 5 Level (EuroQol-5D 5L) Index Value

The EuroQol-5D (version 5L) is a brief self-administered, validated instrument consisting of 2 parts.The first part consists of 5 descriptors of current health state (mobility, self care, usual activities, pain/discomfort, and anxiety/ depression); a participant is asked to rate each state on a five level scale (no problem, slight problem, moderate problem, severe problem and extreme problem) with higher levels indicating greater severity/ impairment. Published weights are available that allow for the creation of a single summary score called the EQ-5D index that ranges from 0 to 1, with low scores representing a higher level of dysfunction and 1 as perfect health. Minimally important differences in the EQ-5D index score are 0.06 or greater in cancer patients. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, Visit, Treatment\*Visit and Baseline.

Time frame:
Baseline, End of Study (Up to 32 Months)
Reported as:
Least squares mean · units on a scale
Change From Baseline to End of Study in Health Status on the EuroQuol 5-Dimension 5 Level (EuroQol-5D 5L) Index Value
units on a scaleAbemaciclib + NSAIPlacebo + NSAI
Change From Baseline to End of Study in Health Status on the EuroQuol 5-Dimension 5 Level (EuroQol-5D 5L) Index Value0.01 ± 0.010.01 ± 0.01
Statistical analysis
  • Abemaciclib + NSAI vs Placebo + NSAI · Mixed Models Analysis · p = 0.688 · Mean difference (net): -0.01
SecondaryChange From Baseline to End of Study in Health Status on the EuroQol-5D 5L Visual Analog Scale (VAS) Scores Scale

The EuroQol-5D (version 5L) is a brief self-administered, validated instrument consisting of 2 parts. The second part consists of the EQ-5D general health status as measured by a visual analog scale (EQ-5D VAS). EQ-5D VAS measures the participant's self-rated health status on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state). Minimally important differences in the EQ-5D VAS score are 7 or greater in cancer patients. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, Visit, Treatment\*Visit and Baseline.

Time frame:
Baseline, End of Study (Up to 32 Months)
Reported as:
Least squares mean · millimeter (mm)
Change From Baseline to End of Study in Health Status on the EuroQol-5D 5L Visual Analog Scale (VAS) Scores Scale
millimeter (mm)Abemaciclib + NSAIPlacebo + NSAI
Change From Baseline to End of Study in Health Status on the EuroQol-5D 5L Visual Analog Scale (VAS) Scores Scale0.49 ± 0.781.51 ± 1.15
Statistical analysis
  • Abemaciclib + NSAI vs Placebo + NSAI · Mixed Models Analysis · p = 0.466 · Mean difference (net): -1.01
SecondaryPharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity [AUC(0-∞)] of Abemaciclib and Its Metabolites M2 and M20

Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity \[AUC(0-∞)\] of Abemaciclib and Its Metabolites M2 and M20

Time frame:
Cycle 1 Day 1; 2 to 4 hours (h) post dose, Cycle 2 Day 1; 3 h post dose; 7 h post dose, Cycle 3 Day 1; pre dose, 3 h post dose
Reported as:
Geometric mean · nanogram*hours/milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity [AUC(0-∞)] of Abemaciclib and Its Metabolites M2 and M20
nanogram*hours/milliliter (ng*h/mL)Abemaciclib + NSAI
Abemaciclib3360 ± 36.6
M21290 ± 75.8
M202300 ± 74.4
SecondaryPK: Hepatic Clearance of Abemaciclib, and Apparent Hepatic Clearance of Its Metabolites M2 and M20

PK: Hepatic Clearance of Abemaciclib, and apparent hepatic clearance of its Metabolites M2 and M20

Time frame:
Cycle 1 Day 1; 2 to 4 hours (h) post dose, Cycle 2 Day 1; 3 h post dose; 7 h post dose, Cycle 3 Day 1; pre dose, 3 h post dose
Reported as:
Geometric mean · liters/hour (L/h)
PK: Hepatic Clearance of Abemaciclib, and Apparent Hepatic Clearance of Its Metabolites M2 and M20
liters/hour (L/h)Abemaciclib + NSAI
Abemaciclib23.0 ± 26.7
M221.6 ± 50.4
M2026.0 ± 46.4

Adverse events

Collected over Baseline Up to 32 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abemaciclib + NSAI63/328 (19.2%)102/327 (31.2%)322/327 (98.5%)
Placebo + NSAI30/165 (18.2%)27/161 (16.8%)141/161 (87.6%)
Most frequent serious events
Showing 10 of 105
Most frequent serious events
EventAbemaciclib + NSAIPlacebo + NSAI
Lung infectionInfections and infestations13/3270/161
EmbolismVascular disorders8/3271/161
AnaemiaBlood and lymphatic system disorders6/3270/161
DiarrhoeaGastrointestinal disorders5/3270/161
Acute kidney injuryRenal and urinary disorders5/3270/161
Abdominal painGastrointestinal disorders1/3272/161
VomitingGastrointestinal disorders2/3272/161
DehydrationMetabolism and nutrition disorders4/3272/161
Urinary tract infectionInfections and infestations4/3271/161
PneumonitisRespiratory, thoracic and mediastinal disorders4/3270/161
Most frequent other events
Showing 10 of 51
Most frequent other events
EventAbemaciclib + NSAIPlacebo + NSAI
DiarrhoeaGastrointestinal disorders267/32752/161
NeutropeniaBlood and lymphatic system disorders143/3273/161
NauseaGastrointestinal disorders135/32733/161
FatigueGeneral disorders135/32754/161
AnaemiaBlood and lymphatic system disorders102/32713/161
Abdominal painGastrointestinal disorders102/32720/161
VomitingGastrointestinal disorders98/32720/161
AlopeciaSkin and subcutaneous tissue disorders90/32718/161
Decreased appetiteMetabolism and nutrition disorders86/32717/161
LeukopeniaBlood and lymphatic system disorders72/3274/161

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Abemaciclib + NSAIPlacebo + NSAITotal
Mean63.13 ± 9.9262.92 ± 9.9663.05 ± 9.92
Sex: Female, Male
Sex: Female, Male(Participants)Abemaciclib + NSAIPlacebo + NSAITotal
Female328165493
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Abemaciclib + NSAIPlacebo + NSAITotal
Hispanic or Latino321244
Not Hispanic or Latino230125355
Unknown or Not Reported662894
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Abemaciclib + NSAIPlacebo + NSAITotal
American Indian or Alaska Native437
Asian10345148
Native Hawaiian or Other Pacific Islander011
Black or African American538
White186102288
More than one race202
Unknown or Not Reported281139
Region of Enrollment
Region of Enrollment(Participants)Abemaciclib + NSAIPlacebo + NSAITotal
Australia9615
Austria10313
Belgium14721
Canada141125
Germany11516
Spain161430
France301141
United Kingdom729
Greece011
Israel281947
Italy111122
Japan381553
South Korea411859
Mexico22729
Netherlands246
New Zealand101
Russia13619
Slovakia202
Sweden314
Turkey9312
Taiwan23932
United States241236
08

Study locations

155 sites

Showing the first 100 of 155 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Tredan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017 Nov 10;35(32):3638-3646. doi: 10.1200/JCO.2017.75.6155. Epub 2017 Oct 2. PubMed 28968163 ↗
  • Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, Frenzel M, Hardebeck MC, Cox J, Barriga S, Toi M, Iwata H, Goetz MP. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019 Jan 17;5:5. doi: 10.1038/s41523-018-0097-z. eCollection 2019. PubMed 30675515 ↗
  • Hong J, Chen T, Ouyang L, Du N, Li A, Zhou Z, Zhang H, Xia Z, Meng J. Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2- advanced breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2024 Apr;24(4):559-566. doi: 10.1080/14737167.2024.2330542. Epub 2024 Mar 20. PubMed 38470447 ↗
  • Rugo HS, Harmer V, O'Shaughnessy J, Jhaveri K, Tolaney SM, Cardoso F, Bardia A, Maheshwari VK, Tripathi S, Haftchenary S, Pathak P, Fasching PA. Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2- advanced breast cancer: a matching-adjusted indirect comparison. Ther Adv Med Oncol. 2023 Feb 24;15:17588359231152843. doi: 10.1177/17588359231152843. eCollection 2023. PubMed 36861085 ↗
  • Takahashi M, Tokunaga E, Mori J, Tanizawa Y, van der Walt JS, Kawaguchi T, Goetz MP, Toi M. Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Breast Cancer. 2022 Jan;29(1):174-184. doi: 10.1007/s12282-021-01295-0. Epub 2021 Oct 18. PubMed 34661821 ↗
  • Goetz MP, Okera M, Wildiers H, Campone M, Grischke EM, Manso L, Andre VAM, Chouaki N, San Antonio B, Toi M, Sledge GW Jr. Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. Breast Cancer Res Treat. 2021 Apr;186(2):417-428. doi: 10.1007/s10549-020-06029-y. Epub 2021 Jan 3. PubMed 33392835 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Jan 2017, 26 months.

Results were first posted in Mar 2018, 1 year 1 month after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 26 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2014
First posted
Sep 23, 2014
StartActual
Nov 6, 2014
Primary completionActual
Jan 31, 2017
CompletionEst.
Dec 2026
Results first posted
Mar 23, 2018
Last update
Feb 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02246621
Responsible party
Sponsor
First posted
Sep 23, 2014
Start date
Nov 6, 2014
Primary completion
Jan 31, 2017
Completion
Dec 2026 (estimated)
Results posted
Mar 23, 2018
Last update
Feb 3, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion